Silo Pharma Inc. (NASDAQ: SILO) has received a Notice of Allowance from the United States Patent and Trademark Office for a patent application covering its lead intranasal therapeutic, SPC-15, aimed at treating post-traumatic stress disorder (PTSD). The patent, titled “Compositions and Methods for the Prevention of Stress-Induced Fear, Depressive-Like and Anxiety-Like Behavior,” encompasses both composition and method claims for Silo’s proprietary approach to preventing or delaying stress-induced behavioral responses. This development marks a significant milestone for the company as it advances SPC-15 through the development pipeline.
A Notice of Allowance signifies that the USPTO has completed its examination and determined that the application meets all requirements for patentability, meaning the patent will be granted shortly. This U.S. patent protection is a critical component of Silo’s strategy to commercialize SPC-15 for PTSD, adding to its growing portfolio of biopharmaceutical intellectual property. The allowance follows the issuance of a corresponding patent by the Japan Patent Office earlier this year, underscoring the global recognition of Silo’s innovative approach.
The implications of this patent allowance are substantial. PTSD is a debilitating condition that affects millions worldwide, and current treatment options often have limitations. SPC-15, with its intranasal delivery and novel mechanism, could offer a new therapeutic avenue for patients. By securing patent protection in the U.S., Silo Pharma not only fortifies its competitive position but also enhances its ability to attract partnerships and funding for further clinical development. The patent covers methods for preventing stress-induced fear, depressive-like and anxiety-like behaviors, which are core symptoms of PTSD, suggesting broad potential applications beyond PTSD alone.
Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company focused on underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system diseases. Its portfolio includes SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. The company collaborates with leading universities and laboratories to drive its research forward.
For investors, this patent allowance reduces regulatory risk and validates the company’s scientific approach. It also paves the way for potential licensing deals or collaborations with larger pharmaceutical companies. To view the full press release, visit https://ibn.fm/Hh4Z6. For the latest news and updates relating to SILO, visit the company’s newsroom at https://ibn.fm/SILO.
The broader impact of this announcement extends to the mental health treatment landscape. With the rising prevalence of PTSD and the urgent need for effective therapies, Silo’s progress could contribute to addressing a significant unmet medical need. The patent allowance also highlights the importance of intellectual property in the biopharmaceutical industry, where protection is essential for recouping research and development costs and ensuring market exclusivity. As Silo continues to develop SPC-15, this patent will be a cornerstone of its value proposition.
